Last Updated: 25 Aug 2025
Source: Statifacts
Biopharma Product Testing Market (By Type: Chemical Analysis, Bioanalysis, and Others; By Application: Pharmaceutical Research Institute, Hospital, and Others; By Region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) Industry Size, Share, Growth, Trends 2025 to 2034.
The biopharma product testing market size was US$ 8.92 billion in 2024 and is forecasted to hit US$ 24.89 billion by 2034 with a CAGR of 10.8% during the period between 2025 and 2034. The market is growing significantly due to high demand for biologics, new regulatory oversight requiring frequent testing, and overall growth of the pharmaceutical sector.
| Reports Attributes | Statistics |
| Market Size in 2024 | USD 8.92 Billion |
| Market Size in 2025 | USD 9.89 Billion |
| Market Size in 2031 | USD 18.3 Billion |
| Market Size by 2034 | USD 24.89 Billion |
| CAGR 2025 to 2034 | 10.80% |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
The rise in demand for monoclonal antibodies, gene and cell therapies, is due to groundbreaking new research such as CRISPR-Cas9 and molecular mapping. The development of these novel therapies is driving demand for testing, with new regulatory frameworks being developed by organizations such as the U.S. Food and Drug Administration, the European Medicines Agency, and ICH to ensure patient safety. Such demands are pushing companies toward outsourcing to contract research organizations (CROs) and contract development & manufacturing organizations (CDMOs) allows biopharma firms to leverage cheaper infrastructure, labor, and import expertise for cost-effective R&D and production. Industry players are expanding testing capacity via new labs, strategic partnerships, and centers of excellence, with larger investments made through fewer rounds.
Despite this growth, the high cost of testing and infrastructure, especially with the prohibitive costs associated with advanced analytical tools like HRMS, NGS, and labor shortages in GMP/GLP labs, bioinformatics fields, is hampering the expansion of the biopharma product testing market. However, the implementation of artificial intelligence (AI) and Machine Learning is set to revolutionize the market in the next few years due to automation of data analysis and error detection, along with predictive modeling for stability and toxicity studies. The use of digital twins and blockchain integration is also expected to grow the biopharma product testing space.
| Regions | Shares (%) |
| North America | 40% |
| Asia Pacific | 30% |
| Europe | 20% |
| LAMEA | 10% |
| Segments | Shares (%) |
| Chemical Analysis | 45% |
| Bioanalysis | 40% |
| Others | 15% |
| Segments | Shares (%) |
| Pharmaceutical Research Institute | 50% |
| Hospital | 30% |
| Others | 20% |
